Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy
| العنوان: | Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy |
|---|---|
| المؤلفون: | David A. Mrazek, Ashwini Shewade, John Hornberger, C. Anthony Altar, Jill Garrison, Victor Cruz |
| المصدر: | International Review of Psychiatry. 25:509-533 |
| بيانات النشر: | Informa UK Limited, 2013. |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | Serotonin Plasma Membrane Transport Proteins, medicine.medical_specialty, CYP2D6, Polymorphism, Genetic, business.industry, medicine.medical_treatment, CYP2C19, medicine.disease, Antidepressive Agents, Psychiatry and Mental health, Pharmacotherapy, Cytochrome P-450 Enzyme System, Schizophrenia, Receptors, Serotonin, Pharmacodynamics, Humans, Medicine, Antidepressant, business, Psychiatry, Antipsychotic, Adverse effect, Antipsychotic Agents |
| الوصف: | Adverse events, response failures and medication non-compliance are common in patients receiving medications for the treatment of mental illnesses. A systematic literature review assessed whether pharmacokinetic (PK) or pharmacodynamic (PD) responses to 26 commonly prescribed antipsychotic and antidepressant medications, including efficacy or side effects, are associated with nucleotide polymorphisms in eight commonly studied genes in psychiatric pharmacotherapy: CYP2D6, CYP2C19, CYP2C9, CYP1A2, CYP3A4, HTR2C, HTR2A, and SLC6A4. Of the 294 publications included in this review, 168 (57%) showed significant associations between gene variants and PK or PD outcomes. Other studies that showed no association often had insufficient control for confounding variables, such as co-medication use, or analysis of medications not substrates of the target gene. The strongest gene-outcome associations were for the PK profiles of CYP2C19 and CYP2D6 (93% and 90%, respectively), for the PD associations between HTR2C and weight gain (57%), and for SLC6A4 and clinical response (54%), with stronger SLC6A4 response associations for specific drug classes (60-83%). The preponderance of evidence supports the validity of analyzing nucleotide polymorphisms in CYP and pharmacodynamic genes to predict the metabolism, safety, or therapeutic efficacy of psychotropic medications commonly used for the treatment of depression, schizophrenia, and bipolar illness. |
| تدمد: | 1369-1627 0954-0261 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d0c1c09ee5098c8c8498473944f963b https://doi.org/10.3109/09540261.2013.825579 |
| رقم الأكسشن: | edsair.doi.dedup.....5d0c1c09ee5098c8c8498473944f963b |
| قاعدة البيانات: | OpenAIRE |
PDF full text from Publisher | تدمد: | 13691627 09540261 |
|---|